» Articles » PMID: 32149275

Macrophages in Obesity and Non-alcoholic Fatty Liver Disease: Crosstalk with Metabolism

Overview
Journal JHEP Rep
Specialty Gastroenterology
Date 2020 Mar 10
PMID 32149275
Citations 127
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and a major cause of liver cirrhosis and hepatocellular carcinoma. NAFLD is intimately linked with other metabolic disorders characterized by insulin resistance. Metabolic diseases are driven by chronic inflammatory processes, in which macrophages perform essential roles. The polarization status of macrophages is itself influenced by metabolic stimuli such as fatty acids, which in turn affect the progression of metabolic dysfunction at multiple disease stages and in various tissues. For instance, adipose tissue macrophages respond to obesity, adipocyte stress and dietary factors by a specific metabolic and inflammatory programme that stimulates disease progression locally and in the liver. Kupffer cells and monocyte-derived macrophages represent ontologically distinct hepatic macrophage populations that perform a range of metabolic functions. These macrophages integrate signals from the gut-liver axis (related to dysbiosis, reduced intestinal barrier integrity, endotoxemia), from overnutrition, from systemic low-grade inflammation and from the local environment of a steatotic liver. This makes them central players in the progression of NAFLD to steatohepatitis (non-alcoholic steatohepatitis or NASH) and fibrosis. Moreover, the particular involvement of Kupffer cells in lipid metabolism, as well as the inflammatory activation of hepatic macrophages, may pathogenically link NAFLD/NASH and cardiovascular disease. In this review, we highlight the polarization, classification and function of macrophage subsets and their interaction with metabolic cues in the pathophysiology of obesity and NAFLD. Evidence from animal and clinical studies suggests that macrophage targeting may improve the course of NAFLD and related metabolic disorders.

Citing Articles

FIB-4 Index Can Predict Mortality in Hospitalized Patients with COVID-19 Infection, Independent of CT Severity Score.

Salahshour F, Karimpour Reyhan S, Zendedel K, Seifouri K, Seyyedsalehi M, Naghavi P Arch Iran Med. 2025; 28(2):88-94.

PMID: 40062496 PMC: 11892101. DOI: 10.34172/aim.33514.


Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.


Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease.

Cho Y, Kwon Y, Hwang S Liver Res. 2025; 7(1):16-25.

PMID: 39959694 PMC: 11791820. DOI: 10.1016/j.livres.2022.06.001.


Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study.

Heyens L, Kenjic H, Dagnelie P, Schalkwijk C, Stehouwer C, Meex S BMJ Open Gastroenterol. 2024; 11(1).

PMID: 39615896 PMC: 11624825. DOI: 10.1136/bmjgast-2024-001466.


Crosstalk between macrophages and immunometabolism and their potential roles in tissue repair and regeneration.

Ma H, Gao L, Chang R, Zhai L, Zhao Y Heliyon. 2024; 10(18):e38018.

PMID: 39381218 PMC: 11458987. DOI: 10.1016/j.heliyon.2024.e38018.


References
1.
McNelis J, Olefsky J . Macrophages, immunity, and metabolic disease. Immunity. 2014; 41(1):36-48. DOI: 10.1016/j.immuni.2014.05.010. View

2.
Lodder J, Denaes T, Chobert M, Wan J, El-Benna J, Pawlotsky J . Macrophage autophagy protects against liver fibrosis in mice. Autophagy. 2015; 11(8):1280-92. PMC: 4590651. DOI: 10.1080/15548627.2015.1058473. View

3.
Chan K, Pillon N, Sivaloganathan D, Costford S, Liu Z, Theret M . Palmitoleate Reverses High Fat-induced Proinflammatory Macrophage Polarization via AMP-activated Protein Kinase (AMPK). J Biol Chem. 2015; 290(27):16979-88. PMC: 4505442. DOI: 10.1074/jbc.M115.646992. View

4.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

5.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View